Question

Difficulty: MediumGynecologic Oncology

During a health maintenance visit, a 5454-year-old woman (G2P2) returns to the clinic to discuss the results of her recent cervical cancer screening. Two weeks prior, she underwent a routine Pap test and reported a self-resolving episode of brownish vaginal spotting. She reached menopause at age 5050 and does not take hormone replacement therapy. Her past medical history is notable for obesity with a body mass index of 3232 and well-controlled hypertension. The cytology report indicates atypical glandular cells (AGC), and high-risk human papillomavirus (HPV) co-testing is negative. Pelvic examination demonstrates a parous, normal-appearing cervix without visible lesions, and bimanual examination reveals a mobile, non-tender uterus of normal size. Which of the following is the most appropriate next step in the diagnostic workup for this patient?

  1. Colposcopy, endocervical sampling, and endometrial biopsyAnswer
  2. B
    Colposcopy and endocervical sampling only
  3. C
    Transvaginal ultrasonography
  4. D
    Diagnostic conization of the cervix
  5. E
    Repeat cervical cytology in 12 months

Answer

Colposcopy, endocervical sampling, and endometrial biopsy
This patient presents with a Pap test showing atypical glandular cells (AGC) and a history of postmenopausal bleeding (spotting), both of which are independent indications for endometrial evaluation. AGC is associated with a significant risk of underlying neoplastic conditions, including cervical adenocarcinoma in situ, invasive cervical cancer, endometrial hyperplasia, and endometrial cancer. The American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines mandate that all women age 35 or older with AGC on cytology must undergo colposcopy, endocervical sampling (curettage), and endometrial biopsy. This comprehensive triad evaluates the ectocervix, endocervical canal, and endometrial cavity simultaneously, ensuring no occult malignancy is missed.

Step-by-Step Solution

1
Analyze the patient's presentation and cytology report.
The patient is a 5454-year-old postmenopausal woman with an episode of spotting, obesity, and an Atypical Glandular Cells (AGC) Pap test result.
Identifying the specific cytological abnormality and patient risk factors (age > 35, PMB, obesity) determines the required clinical algorithm.
2
Determine the source of glandular cells on a Pap test.
Atypical glandular cells can originate from the endocervix or the endometrium.
Unlike squamous abnormalities, AGC indicates a high risk for glandular neoplasia, such as cervical adenocarcinoma in situ or endometrial cancer.
3
Select the appropriate diagnostic procedure based on oncologic guidelines.
Guidelines mandate colposcopy, endocervical sampling, and endometrial biopsy for women 35 years or older with AGC.
This specific diagnostic triad ensures complete histological sampling of all potential anatomic sources for the atypical glandular cells, preventing a missed cancer diagnosis.

Key Concept

Management of Atypical Glandular Cells (AGC) on cervical cytology in women over age 35 or with endometrial risk factors.
Estimated Time:1m 15s
Rate this question